Diabetes (type 2) - exenatide (prolonged release)

Prolonged release exenatide for the second-line (dual therapy) or third-line (triple therapy) treatment of type 2 diabetes

Status: History
Expected date of issue: February 2012
Process: STA
Topic area:
  • Endocrine, nutritional and metabolic

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Kumar Perampaladas and Linda Landells
Communications manager: Shalu Kanal
Project manager: Bijal Joshi


Provisional schedule

Closing date for invited submissions / evidence submission: 17 June 2011
1st appraisal committee meeting: 20 September 2011
2nd appraisal committee meeting 16 November 2011


Consultees and commentators

Consultees Commentators (no right to submit or appeal)


  • Eli Lilly (exenatide)

Patient/carer groups

  • Afiya Trust
  • Black and Ethnic Minority Diabetes Association (BEMDA)
  • Black Health Agency
  • Chinese National Healthy Living Centre
  • Counsel and Care
  • Diabetes Research & Wellness Foundation
  • Diabetes UK
  • Equalities National Council
  • Muslim Council of Britain
  • Muslim Health Network
  • National Obesity Forum
  • Network of Sikh Organisations
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • Surya Foundation

Professional groups

  • Association of British Clinical Diabetologists
  • British Association for Services to the Elderly
  • British Diabetic Association
  • British Geriatrics Society
  • Diabetes Monitoring Forum
  • National Diabetes Nurse Consultant Group
  • Primary Care Diabetes Society
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • Royal Society of Medicine – Intellectual Disabilities Forum
  • United Kingdom Clinical Pharmacy Association


  • Department of Health
  • Enfield NHS PCT
  • NHS Redcar and Cleveland
  • Welsh Assembly Government


  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Diabetes UK Cymru
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • National Association of Primary Care
  • National Pharmacy Association
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • Public Health Wales NHS Trust
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • Accord Healthcare (gliclazide)
  • Actavis UK (glimepiride, glipizide, tolbutamide, gliclazide)
  • Arrow Generics (glibenclamide, gliclazide)
  • AstraZeneca (saxagliptin)
  • Bristol Myers Squibb (saxagliptin)
  • C P Pharmaceuticals (insulin)
  • Covidien UK (insulin)
  • Dr Reddy's Labs (glimepiride)
  • Eli Lilly (insulin, insulin analogues)
  • Kent Pharmaceuticals (glibenclamide, glimepiride, glipizide, tolbutamide, gliclazide)
  • Merck Sharp & Dohme (sitagliptin)
  • Mylan (glibenclamide, glipizide, tolbutamide, gliclazide)
  • Novartis Pharmaceuticals UK (metformin, vildagliptin)
  • Novo Nordisk (insulin, insulin analogues, liraglutide)
  • Pfizer (glipizide, insulin)
  • Ranbaxy UK (glimepiride)
  • Rosemont Pharmaceuticals (metformin)
  • Sandoz (glimepiride, glipizide, gliclazide)
  • Sanofi-Aventis (glibenclamide glimepiride, insulin, insulin analogues)
  • Servier Laboratories (gliclazide)
  • Takeda UK (metformin, pioglitazone)
  • Teva UK (glimepiride, gliclazide, glipizide, glibenclamide)
  • Winthrop Pharmaceuticals UK (glimepiride, gliclazide)
  • Wockhardt UK (glibenclamide, insulin, metformin, gliclazide)

Relevant research groups

  • Diabetes Foundation
  • Heart Disease and Diabetes Research Trust
  • MRC Clinical Trials Unit
  • National Institute for Health Research
  • Research Institute for the Care of Older People

Evidence Review Group

  • Warwick Evidence
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guidelines Centre
  • National Collaborating Centre for Women’s and Children’s Health

Associated public health groups

  • None



Project history

Date Update

17 November 2010   


Please note that following on from information received from the manufacturer, this appraisal has been rescheduled, in order for the inclusion of significant clinical trial data from a head to head comparator study that will soon be available earlier than expected.

Therefore, we now anticipate that the appraisal will begin during mid April 2011 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2011.




Key documents

This page was last updated: 27 April 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.